Table 2.
Association of the Hypothalamic-Pituitary-Adrenal axisalleles with chronic overall pain severity
| SNP | Gene | Alleles | MAF | Overall pain | |||
|---|---|---|---|---|---|---|---|
| Homozygous Major |
Heterozygous | Homozygous Minor |
p-valuea | ||||
| rs258763 | NR3C1 | T/A | 0.43 | 3.5 (3.2, 3.8) | 3.4 (3.2, 3.7) | 3.5 (3.1, 3.8) | 0.83 |
| rs9324916 | NR3C1 | C/G | 0.23 | 3.4 (3.2, 3.6) | 3.4 (3.2, 3.7) | 4.1 (3.4, 4.7) | 0.57 |
| rs2963155 | NR3C1 | A/G | 0.21 | 3.4 (3.2, 3.6) | 3.5 (3.3, 3.8) | 3.5 (2.8, 4.2) | 0.46 |
| rs9324918 | NR3C1 | A/G | 0.14 | 3.5 (3.3, 3.6) | 3.5 (3.2, 3.9) | 3.1 (2.1, 4.0) | 0.81 |
| rs9324924 | NR3C1 | G/T | 0.33 | 3.4 (3.2, 3.6) | 3.5 (3.3, 3.8) | 3.5 (3.0, 3.9) | 0.47 |
| rs12942300 | CRHR1 | T/A | 0.15 | 3.5 (3.3, 3.7) | 3.3 (3.0, 3.6) | 3.3 (2.4, 4.2) | 0.18 |
| rs7209436 | CRHR1 | C/T | 0.43 | 3.3 (3.0, 3.6) | 3.6 (3.3, 3.8) | 3.5 (3.1, 3.8) | 0.16 |
| rs4792887 | CRHR1 | C/T | 0.09 | 3.5 (3.3, 3.7) | 3.4 (3.0, 3.8) | 3.9 (2.2, 5.6) | 0.77 |
| rs17689378 | CRHR1 | C/T | 0.23 | 3.4 (3.2, 3.6) | 3.5 (3.2, 3.8) | 3.5 (2.8, 4.1) | 0.67 |
| rs12936511 | CRHR1 | C/T | 0.03 | 3.5 (3.3, 3.6) | 3.5 (2.9, 4.2) | 3.5 (0.9, 6.2) | 0.81 |
| rs81189 | CRHR1 | G/C | 0.48 | 3.3 (3.0, 3.6) | 3.6 (3.4, 3.8) | 3.4 (3.1, 3.7) | 0.18 |
| rs16940665 | CRHR1 | T/C | 0.23 | 3.4 (3.2, 3.6) | 3.5 (3.3, 3.8) | 3.5 (2.8, 4.1) | 0.62 |
| rs16940674 | CRHR1 | C/T | 0.23 | 3.4 (3.2, 3.6) | 3.5 (3.2, 3.8) | 3.5 (2.9, 4.2) | 0.64 |
| rs7718461 | CRHBP | A/G | 0.38 | 3.1 (2.9, 3.3) | 3.5 (3.2, 3.7) | 3.5 (3.4, 3.7) | 0.0012b |
| rs1875999 | CRHBP | A/G | 0.34 | 3.2 (3.0, 3.4) | 3.5 (3.4, 3.7) | 3.4 (3.1, 3.7) | 0.0061 |
| rs1053989 | CRHBP | G/T | 0.37 | 3.1 (3.0, 3.3) | 3.5 (3.4, 3.7) | 3.4 (3.1, 3.7) | 0.0054 |
| rs3800373 | FKBP5 | T/G | 0.30 | 3.1 (2.9, 3.3) | 3.7 (3.4, 3.9) | 3.5 (2.9, 4.0) | 0.0004b |
a
Repeated measures regression model (6 weeks, 6 month, 1 year), dominant genetic model, adjusted for week, past pain severity, sex, study site.
b
p values are significant after controlling for multiple testing using the method of principal components (the number of effective tests is 12, adjusted significance threshold is 0.05/12 = 0.0042)